Endocrinology

Our endocrinology month in review spotlights the most popular content from the past month. Our top content from September 2022 includes new guideline recommendations from the ADA/EASD, new data on semaglutide 2.4 mg and tirzepatide, a label update for finerenone, & more!

Diabetes mortality rates in 2017-2018 compared with 1999-2000 were highest and unchanged in rural counties.

Announced on September 20, the alerts from the FDA and Medtronic notify users of a potential cybersecurity risk identified through internal testing at Medtronic that would allow unauthorized users to the pump's communication protocol, which could allow unauthorized boluses.

An analysis of nearly 15 years of follow-up data from 97 patients who underwent bariatric surgery during adolescence provides insight into the benefits of surgery on weight loss and comorbidities among those with severe obesity.

Study data suggest HbA1c level from diabetes diagnosis is a strong biomarker for PDR and nephropathy, with the prevalence of both increasing more than 30 years after diagnosis.

A retrospective analysis of EMR data from Mayo Clinic referral centers provides an overview of the effects of 2.4 mg semaglutide on weight loss in populations outside of clinical trial settings.

New research from a team at University of Texas Southwestern describes the impact of the COVID-19 pandemic on mental health and subsequent increases in body weight among people with obesity.

Lifestyle interventions increased weight-specific quality of life in Latino youth with diabetes compared with usual care.

People with diabetes in Italy and the UK reported the highest rates of anxiety at 63% and 51%, respectively.

On September 1, Bayer announced the US FDA had approved a label update for finerenone (Kerendia), which received initial approval in July 2021 for chronic kidney disease associated with type 2 diabetes, to include cardiovascular outcomes data from the FIGARO-DKD trial.

In his most recent column, Dr. Gregory Weiss provides perspective on recent data elucidating the links between insulin sensitivity, central adiposity, and atherosclerosis.

An analysis of more than 11 million women in China details associations between preconception thyroid dysfunction, measured as thyrotropin levels, and delayed time to pregnancy and risk of spontaneous abortion.

An analysis assessing the benefits of hybrid closed loop systems in patients with T1D has returned results suggesting improved glycemic control could help preserve neurological function among adolescents with type 1 diabetes.

A new study suggests there is little difference in weight loss and diabetes outcomes for Black and Hispanic patients undergoing RYGB vs sleeve gastrectomy, but significant differences were observed for safety outcomes with sleeve gastrectomy vs RYGB.

Our latest case report from Brady Pregerson, MD, features a woman in her late 70s with a history of AF on rivaroxaban brought to the hospital for 12 hours of coffee ground emesis and epigastric pain. Can you determine the correct diagnosis?

Our endocrinology month in review spotlights the most popular content from the past month. Our top content from August 2022 includes a trial examining time-restricted eating, a pair of FDA decisions, coverage of ADCES 22, and more!

Dr. Gregory Weiss reflects on a recent literature review breaking down different subtypes of pediatric obesity.

In this episode of Diabetes Dialogue, which was filmed just days after the conclusion of ADCES 22, our hosts take the time to dive deeper into the conference, their favorite sessions, and how the ADCES meetings have evolved to the changing role of diabetes care and education specialists over the years.

Real time CGM was significantly greater time in range, lower time below range, and lower glycemic variability compared to intermittently scanned CGM.

Announced on Aug. 22, the US FDA's clearance of the Omnipod 5 AID system in type 1 diabetes for patients aged 2 years and older comes less than 7 months after receiving clearance in patients aged 6 years and older.

In this article, readers will find a collection of the on-site coverage of the Association of Diabetes Care and Education Specialist (ADCES) 2022 annual meeting from Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives.

Despite increasing the rate of diagnoses and healthcare utilization, the GEMS study found a lower glycemic criterion for diagnosis of gestational diabetes was not associated with a reduced risk of negative outcomes for mother and offspring.

Significant rapid improvement were observed in both signs and symptoms of thyroid eye disease at week 6 after 2 infusions of 10mg/kg VRDN-001.

On August 16, the Gerontological Society of America released a 63-page provider toolkit aimed at providing clinicians managing older patients with obesity with necessary tools and resources to improve the recognition and treatment of obesity in this patient population.

Results from a new study highlighted the importance of achieving normal, stable glucose levels for individuals with type 2 diabetes.

In this edition of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, which was filmed on-site at ADCES 22, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with Jennifer Clements, PharmD, following her sessions to discuss her work, her upcoming research interests, and ongoing trends in the field of diabetes management.

The participants who initiated insulin after implementation achieved significantly higher doses at 36 weeks.

Glargine and detemir insulin were modestly associated with a reduced risk of MACE compared to neutral protamine Hagedorn insulin.

Participants in the least deprived group had one quarter the odds of no change/increase in mean HbA1c compared with the most deprived group.

26 weeks of treatment with empagliflozin reduced the myocardial glucose metabolic rate by 45.1% in patients with type 2 diabetes.